New Delhi, Delhi: The central government has announced major relief for patients undergoing treatment for cancer. The government has capped trade margins on 137 anti-cancer medicines, resulting in significant price reductions effective November 9. Prices of several drug brands have been reduced by more than 50%, with the maximum reduction reaching 96.45%. According to government estimates, this decision is expected to save patients approximately ₹3,502.31 crore annually.
According to the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (NPPA) has decided to regulate trade margins on 137 medicines used in cancer treatment. The move aims to control medicine prices and reduce the financial burden on cancer patients who often face high treatment costs.
76 Pharmaceutical Companies Submit Revised MRP Details
According to information released by the ministry, 76 pharmaceutical companies have so far submitted revised Maximum Retail Prices (MRPs) for 121 medicines, covering a total of 1,225 formulations. Following a review of the prices of these formulations, rates for 1,031 formulations have been reduced.
Government data indicates that prices of approximately 600 brands have been reduced by more than 50%. The maximum price reduction has reached 96.45%. This development could particularly benefit patients who require expensive anti-cancer medicines regularly during their treatment.
New Prices to Come into Effect from November 9
Under the government’s decision, the revised prices will become effective from November 9. After this date, the concerned medicines must be sold according to the newly prescribed prices.
The government has directed retail medicine sellers, distributors and hospitals to prominently display the revised price lists at their premises and on their websites.
The objective is to ensure that patients and their families have access to accurate information about medicine prices. It will also help consumers verify the revised rates while purchasing medicines and identify instances of overcharging.
State Drug Controllers Assigned Monitoring Responsibility
The government has assigned state drug controllers the responsibility of monitoring the effective implementation of the order. They will ensure that medicine retailers, distributors and hospitals comply with the revised pricing guidelines.
Decision Taken Following Expert Committee Recommendations
According to the Ministry of Chemicals and Fertilizers, an expert committee constituted under the Directorate General of Health Services (DGHS) submitted its recommendations on October 17.
Based on these recommendations, the NPPA decided to cap trade margins on 137 anti-cancer medicines.
Patients Expected to Save ₹3,502 Crore Every Year
The government estimates that this decision will help cancer patients save approximately ₹3,502.31 crore annually.
Cancer treatment often requires patients to spend substantial amounts on medicines over extended periods, placing considerable financial pressure on patients and their families.
The significant reduction in medicine prices is expected to help lower treatment expenses and make essential cancer medicines more affordable for patients across the country.
